Minerva Neurosciences | NERV - Cash And Equivalent


Minerva Neurosciences reported $82.3M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Adma Biologics USD 136.02M 2.13M Jun/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
AstraZeneca USD 4.89B 2.67B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Cipla INR 10.18B 2.22B Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Eli Lilly USD 8.95B 3.67B Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Novavax USD 191.46M 36.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025